malaria-mission impossible
DESCRIPTION
Malaria is the third leading cause of death due to infectious disease. It affects 300- 500 million people annually worldwide and accounts for over 100 million deaths, mainly in African children under the age of 5 years. A child in Africa dies every 30 seconds of malaria. Years of research and Millions of Dollars have been spend in the quest to eradicate this deadly infectious disease. The War is still on but is the mission impossible. This presentation was made during a graduate class to review the victories and the challenges so far in the treatment and vaccination against this disease. More still need to be done but their seems to be light at the end of the tunnel. Malaria is not inevitable, it can be eradicated, the mission is possible if only we devote ourselves to quality research and we never give-up. (Oseni Saheed Oluwasina (2013))TRANSCRIPT
2
DEFINITION
AETIOLOGY & TAXONOMY
EPIDEMIOLOGY
LIFE CYCLE
MORPHOLOGY
CLINICAL SIGNS
PATHOGENESIS AND IMMUNOLOGY
DIAGNOSIS
CONTROL ( VACCINE DEVELOPMENT)
TREATMENT
3
DEFINITION
A protozoan disease caused by Plasmodium
species of the phylum Apicomplexa.
Transmitted by the bite of infected female
anopheline mosquitoes.
It is characterized by periodic paroxysm with
shaking chills, high fever, heavy sweating.
Anemia and splenomegaly may also occur in
cases. 4
AETIOLOGY
Four species of Plasmodium cause malaria in human. P. vivax (benign tertian malaria) P. ovale (benign tertian malaria) P. malariae (quartan malaria) P. falciparum (malignant tertian malaria) Each species has its own morphologic, biologic, pathogenic, and clinical characteristics.
5
TAXONOMY
Kingdom: Protista
Sub-Kingdom: Protozoa
Phylum: Apicomplexa
Class: Sporozoasida
Order: Eucoccidiorida
Family: Plasmodiidae
Genus: Plasmodium
Specie: P. falciparum 6
EPIDEMIOLOGY
7
EPIDEMIOLOGY
Malaria is the third leading cause of death due to infectious disease.
It affects 300- 500 million people annually worldwide and accounts for over 100million deaths, mainly in African children under the age of 5yrs. A child in Africa dies every 30 seconds of malaria.
Endemic around the tropics and sub-tropics although it is world wide in distribution.
8
FEMALE ANOPELES MOSQUITO 9
TRANSMISSION
DISTRIBUTION OF PLASMODIUM FALCIPARUM
10
DISTRIBUTION OF PLASMODIUM VIVAX
11
WATERSHEDS OF THE AFRICAN CONTINENT
12
Mosquitoes are aquatic insects
Populationdensity
LIFE CYCLE
13
14
LIFE CYCLE CONT’D
15
16
PLASMODIUM MORPHOLOGY
17
PLASMODIUM ANATOMY
18
19
20
EX-FLAGELLATION OF THE MICROGAMETOCYTEOF A MALARIA PARASITE IN MOSQUITO
STOMACH
21
PORTION OF AN INFECTED MOSQUITO STOMACH.
NOTE NUMEROUS OOCYSTS ON OUTER WALL.
22
SPOROZOITES OF MALARIA IN INFECTEDMOSQUITO STOMACH PREPARATION
23
Light Micrograph SEM
ERYTHROCYTIC STAGES OF MALARIA:ALL INFECTIONS BEGIN WITH THE RING STAGE
REGARDLESS OF THE SPECIES
24
Ring stage
25
CLINICAL SIGNS & SYMPTOMSCLINICAL SIGNS & SYMPTOMS
26
Cold stage
MALARIAL PAROXYSM Cold stagefeeling of intense cold vigorous shivering lasts 15-60 minutes Hot stage intense heat dry burning skin throbbing headache lasts 2-6 hours
Sweating stage profuse sweating declining temperature exhausted and weak →sleep lasts 2-4 hours
27
UNCOMPLICATED MALARIA Uncomplicated malaria is defined as:
Symptomatic infection with malaria parasitaemia without signs of severity and/or evidence of vital organ dysfunction.
28
SEVERE MALARIA
Severe malaria is defined as symptomatic malaria in a patient with P. falciparum asexual parasitaemia with one or more of the following complications: Cerebral malaria (unrousable coma not attributable to other causes). Generalised convulsions (> 2 episodes within 24 hours) Severe normocytic anaemia (Ht<15% or Hb < 5 g/dl) Hypoglycaemia (glood glucose < 2.2 mmol/l or 40 mg/dl ) Metabolic acidosis with respiratory distress (arterial pH < 7.35 or bicarbonate <
15 mmol/l)* Fluid and electrolyte disturbances Acute renal failure (urine <400 ml/24 h in adults; 12 ml/kg/24 h in children) Acute pulmonary oedema and adult respiratory distress syndrome* Abnormal bleeding Jaundice Haemoglobinuria Circulatory collapse, shock, septicaema (algid malaria) Hyperparasitaemia (>10% in non-immune; >20% in semi-immune)
29
RELAPSE
A specific attack that it is up to months or even years after the primary attacks.Tachysporozoite grow in the hepatic cell and multiply to form exoerythrocytic schizonts and then invade RBCs to clinic malaria. Bradysporozoites in the liver spend a rest and sleeping times of months or even years , then they start develop in exoerythrocytic stage and erythrocytic stage. at this time, the patient occurs paroxysm , showing as periodic fever like the primary attacks, it is called Relapse.
NB: Relapse only occurs in P.vivax. 30
Paroxysms (acute febrile episodes) associated with synchrony coincide with the Merozoite release.Temperature is normal and patient feels well.P. falciparum may not exhibit classic paroxysms (continuous fever)
31
Plasmodium falciparumPlasmodium falciparum
Plasmodium vivax Plasmodium ovalePlasmodium vivax Plasmodium ovale
Plasmodium malariaePlasmodium malariae
32
Chronic Asymptomatic
Infection
PlacentalMalaria
Anemia
InfectionDuring
Pregnancy
Developmental Disorders;
Transfusions;Death
LowBirth weight
IncreasedInfant
Mortality
Non-severeAcute Febrile
disease
Cerebral
Malaria
Death
CLINICAL PICTURECLINICAL PICTURE
COMPLICATIONS OF MALARIA :CEREBRAL MALARIA
33
COMPLICATIONS OF MALARIA :
34
Child with severe malaria anaemia in conjunction with acidosis and
respiratory distress Pulmonary Edema
35
Hepato-splenomegalyHepato-splenomegaly
survivors partially immunedoften with splenomegaly
MALARIAL HAEMOGLOBINURIA
36
Clinical Picture :
Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency may develop intravascular haemolysis and haemoglobinuria precipitated by Primaquine and other oxidant drugs, even in the absence of malaria.Haemoglobinuria associated with malaria (“blackwater fever”) is uncommon and malarial haemoglobinuria usually presents in adults as severe disease with anaemia and renal failure.
PATHOGENESIS &
IMMUNOLOGY
37
SUSCEPTIBILITY TO MALARIA, ANTIBODY PRODUCTION, AND LETHALITY
38
PATHOGENESIS
39
The functions of most of the metabolic products of P. falciparum are not known. It is known that they are resistant to treatment with proteases.
P. falciparum uses hemoglobin as a source of energy and produces hemozin to digest hemoglobin, this toxin is stored in the pigment of P. falciparum .
This pigment has been linked to over production of tumor necrosis factor alpha, the gamma interferon and interleukin-1.
These are important and natural parts of human immune systems, but over production can lead to fever and the destruction of healthy host cells.
Information for the following slides adapted from: Chen, Q., M. Schlichtherle, and M. Wahlgren. 2000. Molecular aspects of severe malaria. Clin. Microbiol. Rev. 13:439-450
40
TOXICITY AND PATHOGENICITY
Infection by P. falciparum also radically changes the cell membrane of red blood cells.
The membrane of infected cells becomes rigid and the parasite creates channels through the membrane in order to transport nutrients into the cell.
Protein components of the cell membrane are digested by the parasite and are replaced by the “knobs” (electron rich protrusions of ~100 micrometers).
The knobs are used to bind to uninfected RBCs and to the walls of veins and arteries. This is known as rosetting and can lead to some of the most severe complications of malaria, including cerebral malaria, where such rosettes occur in the brain.
41
42
There are five receptors on RBC which are thought to be involved with the formation of rosettes. They include blood group antigens A and B, CD-36, compliment receptor 1 and HS-like GAGs (heparin sulfate glycosaminoglycans).
Rosettes formed in blood types A and B are larger, tighter and stronger than those formed in persons with O type blood. Blood type A is most often affected by severe malaria.
P. Falciparum also binds using knobs to both IgG and IgM.
The reason for having accumulations of IgM is not precisely known, but it is theorized that such accumulations hinder the access of antibodies specific to infected cells and thus help malaria to evade the immune system.
Information for the following slides adapted from: Chen, Q., M. Schlichtherle, and M. Wahlgren. 2000. Molecular aspects of severe malaria. Clin. Microbiol. Rev. 13:439-450
43
ANTIGENIC VARIATION Malaria has many tools to evade the immune system. P. falciparum has a
very high degree of antigenic variation, making it difficult for the immune system to recognize malaria. P. falciparum has two different ways in which to vary which antigens it expresses.
The first way in which this might occur is during the sexually reproducing stage in the lifecycle when P. Falciparum recombines genetic material. This has unlimited potential to change the genome of P. Falciparum.
The second way in which antigenic variation can occur is through variable genes and point mutations during asexually reproducing stages of the lifecycle. P. Falciparum o has several families of variable antigenic genes.
These are var family, the rosettin/ rif family, and the p60 family. With such a large amount of variability available to malaria it is no
wonder that it can successfully evade the immune system and cause many recurring infections if not properly treated.
Information for the following slides adapted from: Chen, Q., M. Schlichtherle, and M. Wahlgren. 2000. Molecular aspects of severe malaria. Clin. Microbiol. Rev. 13:439-450
44
VAR FAMILY
There are ~40-50 genes in the var family with a few exception they are extremely variable. The var genes are scattered throughout the chromosomes, but concentrated on the 4, 7, and 12 chromosomes.
Using the high variability in these regions at least 2% of individuals vary their antigenic expression each generation. These genes are thought to be involved with resistance to chloroquine and to help P. falciparum evade the host’s immune system.
Mutations at this sight are found in 100% of all resistant strains of P. falciparum. The efficacy of the resistance is greater when a mutation also occurs at a sight known as pfmdr1 (P. falciparum multidrug resistance gene).
Information for the following slides adapted from: Chen, Q., M. Schlichtherle, and M. Wahlgren. 2000. Molecular aspects of severe malaria. Clin. Microbiol. Rev. 13:439-450
Dorsey, G., M. R. Kamya, A. Singh, and P. J. Rosenthal. 2001. Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. J. Infect. Dis. 183:1417-1420.
45
CROSS OVER AND VAR FAMILY
46
DRUG-RESISTANT MALARIA
47
Red - chloroquine resistantGreen - chloroquine sensitiveBlack - chloroquine and mefloquine resistant
ENTRY OF SPOROZOITES INTO PARENCHYMAL CELLS OF THE LIVER
48
TRANSMISSION EM OF MEROZOITE ENTERING A RED CELL.
NOTE POINTS OF ATTACHMENT
49
MECHANISMS OF RED CELL INVASIONBY PLASMODIUM
50
TRANSMISSION EM: RBC INFECTED WITH P. FALCIPARUM
51N = Nucleus; F = food vacuole
“Knobs” of histidine-rich protein.Points of attachment to endothelial cell
DIAGNOSIS
52
DIAGNOSIS
LIGHT MICROSCOPYRAPID DIAGNOSTIC TESTSEROLOGY: ELISA KITS- MOLECULAR TECHNIQUES: PCR (18S rRNA
Assay, Nested PCR Assay, real-time PCR), LAMP.
53
54
Trophozoites
GametocyteSch
izont
Cytoplasm
Stippling
Vacuole
Nucleus/chromatin dot
Dr.
Osenium®
LABORATORY DIAGNOSIS OF MALARIA
Plasmodium falciparum
55
Diagnostic Points: Small, regular, fine to
fleshy cytoplasm Infected RBCs not
enlarged Numerous, multiple
infection is common Ring, comma, marginal
or accole forms are seen; often have double chromatin dots
Maurer’s dots not clearly visible
CCMOVBD
Multiple infection
Marginal form
Double chromatin
LABORATORY DIAGNOSIS OF MALARIA
56Rapid diagnostic tests detect malaria antigens
57
Plastic cassette format of RDT
RAPID DIAGNOSTIC TESTS DETECT MALARIA ANTIGENS
58
CONTROL AND
VACCINE DEVELOPMENT
59
RTS,S VACCINE - PRE- ERYTHROCYTIC VACCINE
Hybrid containing the central repeats and most of the C-terminal of the CSP fused with hepatitis B surface antigen
Complex adjuvant mixture AS02 Completely protected six out of seven volunteers Field study in The Gambia showed good short-term
protection A clinical trial in Mozambique and Tanzania showed
delay of infection and reduction in incidence of severe malaria in young children
The vaccine advanced to Phase III trial.
60
61
Liver Stage
SporozoitesPre-erythrocytic
Stage
PRE- ERYTHROCYTIC STAGE VACCINES
How they work:Generates Ab response against sporozoites
and prevents them from invading the liverPrevents intra-hepatic multiplication by
killing parasite-infected hepatocytes Intended Use:
Ideal for travelers - protects against malaria infection
62
63
Merozoites
Asexual
Erythrocytic
Stage
ASEXUAL ERYTHROCYTIC STAGE VACCINES
How they work:Elicit antibodies that will inactivate
merozoites and/or target malarial Ag expressed on RBC surface
Inhibit development of parasite in RBCs Intended Use:
Morbidity reduction in endemic countries
64
65
Malaria: Plasmodium Life Cycle
Sexual
Stage
SEXUAL STAGE VACCINES
How they work:Induces Ab against sexual stage AgPrevents development of infectious
sporozoites in salivary glands of mosquitoes
Prevent or decrease transmission of parasite to new hosts
Intended Use: Decreased malaria transmission
66
VACCINE PORTFOLIO
67
Ad5 CSP/LSA/TRAP
Pre-ClinicalEvaluation
Phase 1+/- Challenge
Phase 1bendemic
Phase 2bendemic Phase 3
MSP-2in ISCOM
PvR IIin AlOH
PvR IIin ASO2
MSP-2in ISA 720
RTS,Sin ASO1
RTS,S in ASO2
Pfs-16
MSP-4
LSA-1in ASO1
LSA-1in ASO 2
MSP-1Cin Alum-CPG
CP2.9in ISA 720
RTS,S in ASO2
DevelopmentManufactureAd5 CSP/LSA/TRAP
AMA-1Cin ISA 720
Pfs-16
MSP-5
Ad5 MSP-AMA 1
MSP-4
AMA-1in ASO1
AMA-1in ASO2
RECENT LANDMARKS IN MALARIA GENOMES - SEQUENCING
2002: Complete genome sequence of P. falciparum A partial sequence of rodent parasite, P. berghei
2005:sequences of several other rodent parasites P. vivax (a human malaria parasite) P. knowlesi (primarily a monkey parasite)
+ sequence of:Human genomeAnopheles mosquito
New Candidates for drug and vaccine pipeline68
OTHER VACCINE AVENUES Several antigens expressed during the blood
stream and liver stage of P. falciparum have been shown to elicit an immune response in humans.
The study showed that liver stage antigen 3 was highly immunogenic and a good candidate for use in a vaccine to prevent the invasion of RBC by P. falciparum. Immune memory of the antigens (especially LSA3) lasted up to 9 months when tested in chimpanzees.
Information for this slide from: Pouniotis DS, Proudfoot O, Minigo G, Hanley JC, Plebanski M. Long-Term Multiepitopic Cytotoxic-T-Lymphocyte Responses Induced in Chimpanzees by Combinations of Plasmodium falciparum Liver-Stage Peptides and Lipopeptides Infection and Immunity, August 2004, p. 4376-4384, Vol. 72, No. 8 69
VACCINATING MOSQUITOES
In mosquitoes, there are proteins on the surface of gametes and ookinets that may prove useful in formulating a vaccine that protects mosquitoes from infection.
Antibodies to these proteins prevent the parasite from taking up residence in the midgut of mosquitoes and forming oocysts. However, in order for such vaccines to reach mosquitoes they must be combined with efforts to vaccinate people living in endemic areas.
70
PARATRANSGENESIS Paratransgenesis is the manipulation of
symbiotic bacteria such as E. coli to make the host immune to a pathogen.
Bacteria are engineered to produce proteins or peptides that either block binding of or kill parasites.
Several bacteria known to live in the anopheles midgut including Escherichia, Pseudomonas , and bacillus .
When fed with E. coli that produced antibodies to P. berghei, Anopheles mosquitoes showed a reduction in oocyst formation of 95%. 71
Transgenic mosquitoes expressing bee venom known as Phospholipidase A2 have also been shown to resist oocyst formation by up to 87%. Synthetic molecules have also been studied as ways of reducing susceptibility.
Anopheles mosquitoes with a synthetic gene expressing SM1 peptide were found to have 82% reduction in formation of oocysts.
Information on this slides from Michael A. Riehle, Prakash Srinivasan, Cristina K. Moreira and Marcelo Jacobs-Lorena. Towards genetic manipulation of wild mosquito populations to combat malaria: advances and challenges. The Journal of Experimental Biology 206, 3809-3816 (2003)
72
CHALLENGES FOR MALARIA VACCINE
Four antigenetically distinct malaria speciesEach has ~6,000 genesFirst gene was only identified in 1983
Immunity in malaria is complex and immunological responses and correlates of protection are incompletely understood.
Identifying and assessing vaccine candidates takes time and is expensive
There is no clear ‘best approach’ for designing a malaria vaccine
73
OTHER CONTROL METHODS
Biological ControlMosquito fishes (Gambusia affinis) have been
found to be predatory on the anopheles larvae.
Chemical Control Spray insecticides: DDVP and so on.Use mosquito nets, screen, or mosquito
repellents to protect the person from mosquito bites.
Physical Control: Eradicate the breeding places of mosquitoes. 74
TREATMENT
75
ACTION OF ANTIMALARIAL DRUG IN THE ACTION OF ANTIMALARIAL DRUG IN THE DIFFERENT LIFE STAGES OF THE MALARIA DIFFERENT LIFE STAGES OF THE MALARIA
PARASITEPARASITE
76
Tissue SchizontocidesTissue Schizontocides•PrimaquinePrimaquine•PyrimethaminePyrimethamine•TetracyclineTetracycline•ProguanilProguanil
Anti-relapse (P.vivax)•PrimaquineBlood Schizontocides
•Chloroquine•Sulfadoxine/Pyrimethamine•Quinine•Quinidine•Artemisinins
GametocycideGametocycidePrimaquinePrimaquine
SporontocidSporontocideses•PrimaquinePrimaquine•PyrimethaminePyrimethamine•ProguanilProguanil
Symptomatic and supportive treatment
Aetiologic treatment
77
SYMPTOMATIC AND SUPPORTIVE TREATMENT
High fever, convulsion, cerebral edema, black water fever, etc.
Keep warm for shaking chill; Physical and chemical deffervescence
methods for high fever, such as ice bag, air condition.
Corticosteroid may be given , if necessary. Diazepam and wintermin for convulsion.
78
AETIOLOGIC TREATMENT
Falciparum easily treated before complications as no relapses and no para-erythrocytic stage
Chloroquine is treatment of choice for sensitive strains of Plasmodia (merozoites)
Primaquine (Hypnozoites) Mefloquineorquinine and doxycycline (Chloroquine
resistant strains of falciparum) Atovaquone and proguanil (Malarone) for Chloroquine
resistance of P. falciparum. Artemether and lumefantrine (newer)
79
CONCLUSION
Malaria is not inevitable, it can be eradicated, the
mission is possible if only we devote ourselves to quality research and we never give-
up.
Oseni Saheed Oluwasina (2013) 80
81
82